<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">29247557</PMID>
      <DateCompleted>
        <Year>2018</Year>
        <Month>08</Month>
        <Day>28</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>08</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1600-079X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>64</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2018</Year>
              <Month>Apr</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of pineal research</Title>
          <ISOAbbreviation>J Pineal Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Combination of melatonin and rapamycin for head and neck cancer therapy: Suppression of AKT/mTOR pathway activation, and activation of mitophagy and apoptosis via mitochondrial function regulation.</ArticleTitle>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/jpi.12461</ELocationID>
        <Abstract>
          <AbstractText>Head and neck squamous cell carcinoma (HNSCC) clearly involves activation of the Akt mammalian target of rapamycin (mTOR) signalling pathway. However, the effectiveness of treatment with the mTOR inhibitor rapamycin is often limited by chemoresistance. Melatonin suppresses neoplastic growth via different mechanisms in a variety of tumours. In this study, we aimed to elucidate the effects of melatonin on rapamycin-induced HNSCC cell death and to identify potential cross-talk pathways. We analysed the dose-dependent effects of melatonin in rapamycin-treated HNSCC cell lines (Cal-27 and SCC-9). These cells were treated with 0.1, 0.5 or 1 mmol/L melatonin combined with 20 nM rapamycin. We further examined the potential synergistic effects of melatonin with rapamycin in Cal-27 xenograft mice. Relationships between inhibition of the mTOR pathway, reactive oxygen species (ROS), and apoptosis and mitophagy reportedly increased the cytotoxic effects of rapamycin in HNSCC. Our results demonstrated that combined treatment with rapamycin and melatonin blocked the negative feedback loop from the specific downstream effector of mTOR activation S6K1 to Akt signalling, which decreased cell viability, proliferation and clonogenic capacity. Interestingly, combined treatment with rapamycin and melatonin-induced changes in mitochondrial function, which were associated with increased ROS production, increasing apoptosis and mitophagy. This led to increase cell death and cellular differentiation. Our data further indicated that melatonin administration reduced rapamycin-associated toxicity to healthy cells. Overall, our findings suggested that melatonin could be used as an adjuvant agent with rapamycin, improving effectiveness while minimizing its side effects.</AbstractText>
          <CopyrightInformation>© 2017 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Shen</LastName>
            <ForeName>Ying-Qiang</ForeName>
            <Initials>YQ</Initials>
            <AffiliationInfo>
              <Affiliation>Biomedical Research Center, Health Sciences Technology Park, University of Granada, Granada, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guerra-Librero</LastName>
            <ForeName>Ana</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Biomedical Research Center, Health Sciences Technology Park, University of Granada, Granada, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fernandez-Gil</LastName>
            <ForeName>Beatriz I</ForeName>
            <Initials>BI</Initials>
            <AffiliationInfo>
              <Affiliation>Biomedical Research Center, Health Sciences Technology Park, University of Granada, Granada, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Florido</LastName>
            <ForeName>Javier</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Biomedical Research Center, Health Sciences Technology Park, University of Granada, Granada, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>García-López</LastName>
            <ForeName>Sergio</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Biomedical Research Center, Health Sciences Technology Park, University of Granada, Granada, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Martinez-Ruiz</LastName>
            <ForeName>Laura</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Biomedical Research Center, Health Sciences Technology Park, University of Granada, Granada, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mendivil-Perez</LastName>
            <ForeName>Miguel</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Medical Research Institute, Faculty of Medicine, University of Antioquia, Medellin, Colombia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Soto-Mercado</LastName>
            <ForeName>Viviana</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>Medical Research Institute, Faculty of Medicine, University of Antioquia, Medellin, Colombia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Acuña-Castroviejo</LastName>
            <ForeName>Darío</ForeName>
            <Initials>D</Initials>
            <Identifier Source="ORCID">0000-0002-9680-1560</Identifier>
            <AffiliationInfo>
              <Affiliation>Biomedical Research Center, Health Sciences Technology Park, University of Granada, Granada, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, Faculty of Medicine, University of Granada, Granada, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>CIBERFES, Ibs.Granada, Hospital Campus de la Salud, Granada, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ortega-Arellano</LastName>
            <ForeName>Hector</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Medical Research Institute, Faculty of Medicine, University of Antioquia, Medellin, Colombia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Carriel</LastName>
            <ForeName>Victor</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Histology, Faculty of Medicine, University of Granada, Granada, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Diaz-Casado</LastName>
            <ForeName>María E</ForeName>
            <Initials>ME</Initials>
            <AffiliationInfo>
              <Affiliation>Biomedical Research Center, Health Sciences Technology Park, University of Granada, Granada, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Reiter</LastName>
            <ForeName>Russel J</ForeName>
            <Initials>RJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cell Systems and Anatomy, UT Health, San Antonio, TX, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rusanova</LastName>
            <ForeName>Iryna</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>Biomedical Research Center, Health Sciences Technology Park, University of Granada, Granada, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>CIBERFES, Ibs.Granada, Hospital Campus de la Salud, Granada, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nieto</LastName>
            <ForeName>Ana</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Biomedical Research Center, Health Sciences Technology Park, University of Granada, Granada, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>López</LastName>
            <ForeName>Luis C</ForeName>
            <Initials>LC</Initials>
            <AffiliationInfo>
              <Affiliation>Biomedical Research Center, Health Sciences Technology Park, University of Granada, Granada, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, Faculty of Medicine, University of Granada, Granada, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>CIBERFES, Ibs.Granada, Hospital Campus de la Salud, Granada, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Escames</LastName>
            <ForeName>Germaine</ForeName>
            <Initials>G</Initials>
            <Identifier Source="ORCID">0000-0003-1256-7656</Identifier>
            <AffiliationInfo>
              <Affiliation>Biomedical Research Center, Health Sciences Technology Park, University of Granada, Granada, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, Faculty of Medicine, University of Granada, Granada, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>CIBERFES, Ibs.Granada, Hospital Campus de la Salud, Granada, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2018</Year>
          <Month>01</Month>
          <Day>09</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>J Pineal Res</MedlineTA>
        <NlmUniqueID>8504412</NlmUniqueID>
        <ISSNLinking>0742-3098</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>EC 2.7.1.1</RegistryNumber>
          <NameOfSubstance UI="C546842">MTOR protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>JL5DK93RCL</RegistryNumber>
          <NameOfSubstance UI="D008550">Melatonin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>W36ZG6FT64</RegistryNumber>
          <NameOfSubstance UI="D020123">Sirolimus</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002294" MajorTopicYN="N">Carcinoma, Squamous Cell</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006258" MajorTopicYN="N">Head and Neck Neoplasms</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008550" MajorTopicYN="N">Melatonin</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D063306" MajorTopicYN="N">Mitophagy</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020123" MajorTopicYN="N">Sirolimus</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077195" MajorTopicYN="N">Squamous Cell Carcinoma of Head and Neck</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">
mTOR
</Keyword>
        <Keyword MajorTopicYN="N">apoptosis</Keyword>
        <Keyword MajorTopicYN="N">head and neck cancer cells</Keyword>
        <Keyword MajorTopicYN="N">melatonin</Keyword>
        <Keyword MajorTopicYN="N">mitochondria</Keyword>
        <Keyword MajorTopicYN="N">mitophagy</Keyword>
        <Keyword MajorTopicYN="N">rapamycin</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2017</Year>
          <Month>8</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2017</Year>
          <Month>12</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2017</Year>
          <Month>12</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2018</Year>
          <Month>8</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2017</Year>
          <Month>12</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">29247557</ArticleId>
        <ArticleId IdType="doi">10.1111/jpi.12461</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
